Panel Supports Symptoms-Based Endpoint For Community-Acquired Bacterial Pneumonia
This article was originally published in The Pink Sheet Daily
A means of standardizing what are subjective criteria must be developed, the advisory committee stressed to FDA Nov. 3.
You may also be interested in...
Panel Gives Mixed Reviews To Using Single Trial For Community-Acquired Pneumonia
The Anti-Infective Drugs Advisory Committee's failure to agree on a preferred approval pathway for antibiotics to treat community-acquired bacterial pneumonia opens the door for FDA to offer several options to industry.
Panel Dives Into Non-Inferiority Margins
Non-inferiority margins have been a tricky issue as antibiotic sponsors strive to show efficacy without large, lengthy and costly trials.
FDA Indicates Flexibility On Evidence To Support Efficacy In Pneumonia
The agency will seek advisory panel input Nov. 3-4 on options for facilitating trials in community-, hospital- and ventilator-acquired pneumonia.